市場調査レポート

商品コード

1654402

ギランバレー症候群の市場規模、シェア、動向分析レポート：治療法別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2025年01月28日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF (Single User License)

USD 5,950 854,241円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 997,811円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,284,951円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ギランバレー症候群市場の成長と動向

Grand View Research, Inc.の最新レポートによると、ギランバレー症候群の世界市場規模は2030年までに10億3,000万米ドルに達すると予測され、予測期間中にCAGR 6.10％で拡大する見込みです。

末梢神経系に影響を及ぼす稀ではあるが深刻な自己免疫疾患であるギランバレー症候群の有病率の増加が、医療セグメントの成長機会を促進しています。企業は、治療方法、診断ツール、患者ケアソリューションの進歩を通じて、この市場拡大に資本投下することができます。免疫グロブリン静注（IVIG）や血漿交換などの効果的な治療法に対する需要が高まっており、病院や小売薬局を通じてこれらの治療法へのアクセスを改善する必要があります。

GBSには複数の病型があり、それぞれに専門的な医療アプローチが必要です。急性炎症性脱髄性多発神経炎（AIDP）は北米と欧州で最も一般的な病型であり、進行性の筋力低下と感覚障害を特徴とします。慢性炎症性脱髄性多発神経炎（CIDP）は、関連疾患ではあるが慢性疾患であり、長期的な管理戦略が必要であるため、治療的介入に対する持続的な需要が生じています。ミラーフィッシャー症候群（MFS）は、よりまれな病態であり、主に眼球運動と協調運動に影響を及ぼし、標的を絞った神経学的治療が必要となります。急性運動軸索神経障害（AMAN）は、アジアとラテンアメリカでより一般的であり、地域特有の診断と治療開発の必要性を強調しています。

ジカ熱などのウイルス感染やその他の新興病原体と関連する可能性のあるGBSが最近発生し、市場の関心が高まっています。患者数の急増は、サーベイランスの強化、早期診断、タイムリーな治療介入の必要性を促し、医療インフラへの投資を後押ししています。政府や製薬会社は、新たな治療法の開発や既存のプロトコルの改善に向けた研究開発を強化しています。GBSの主要治療法であるIVIGと血漿交換に対する大流行による需要は、世界の血漿供給チェーンを圧迫し、代替療法の技術革新を促しています。

SARS-CoV-2感染とGBSのリスク上昇との関連性が研究により指摘されているため、COVID-19の大流行はGBS市場にさらなる影響を与えています。COVID-19感染者の急増は、GBSの診断報告の増加につながり、IVIGと血漿交換治療に対する需要の増加を促しました。さらに、パンデミックに関連した医療のサプライチェーンの混乱は、必要不可欠な治療の入手に影響を及ぼし、医薬品の生産と流通における戦略的調整が必要となりました。ウイルス感染後の神経学的合併症に対する認識と調査の高まりも、GBS診断と治療の革新への投資を後押ししています。

治療方法は進化しており、非経口と経口の選択肢が検討されています。急性期の治療ではIVIGが依然として主流であるが、CIDP患者にとってより利用しやすい長期的な治療法を提供できる可能性がある経口免疫調節療法の調査も活発化しています。薬局はGBS治療の流通において重要な役割を果たしています。IVIGまたは血漿交換療法中は入院治療と綿密なモニタリングが必要なため、病院薬局が市場を独占しています。しかし、小売薬局はCIDP管理における役割を拡大しており、患者に維持療法や支持薬への便利なアクセスを提供しています。

認知度の向上、治療アプローチの進化、医薬品への投資の増加により、GBS市場は大きく成長する見込みです。急性期と慢性期の両方のケアソリューションにおける革新が引き続き状況を形成し、医療、治療におけるビジネスに新たな機会をもたらすと考えられます。

ギランバレー症候群市場レポートハイライト

2024年のギランバレー症候群治療市場は、免疫グロブリン静注（IVIG）が支配的でした。この優位性は、IVIGが免疫反応を調整し、疾患の進行を抑え、回復率を向上させる効果が実証されているためであり、GBSの第一選択治療として好まれています。
急性炎症性脱髄性多発神経炎（AIDP）は、2024年にGBSサブタイプの中で最大の市場シェアを占めました。特に北米と欧州で最も一般的なGBSとして、AIDPの流行は効果的な治療オプションの需要に大きく影響し、市場の優位性をさらに強めています。
2024年のGBS治療市場は非経口剤が牽引。IVIGや血漿交換のような静脈内投与による治療は、この疾患の重大な性質を考慮すると、迅速かつ効果的な治療効果を保証し、急性と重症の両方の症例において患者の転帰を向上させています。
病院薬局は、2024年においても支配的な流通チャネルです。即時の医療介入と専門的治療が必要なため、病院薬局は、特に急性期医療現場において、GBS治療の入手可能性と投与を確保する上で重要な役割を果たしています。
北米がGBS治療市場をリードしたのは、医療インフラが整備されていること、神経疾患に対する意識が高いこと、先進的治療オプションが利用可能であることなどが要因です。同地域は研究とイノベーションに力を入れており、市場の成長をさらに後押ししています。

ギランバレー症候群市場：タイプセグメントダッシュボード
ギランバレー症候群市場：タイプ変動分析、2024年と2030年
急性炎症性脱髄性多発神経炎（AIDP）
慢性炎症性脱髄性多発根神経炎（CIDP）
ミラー・フィッシャー症候群（MFS）
急性運動軸索性ニューロパチー（AMAN）
その他

第6章ギランバレー症候群市場：投与経路別、推定・動向分析

ギランバレー症候群市場：投与経路セグメントダッシュボード
ギランバレー症候群市場：投与経路別変動分析、2024年と2030年
非経口
経口

第7章ギランバレー症候群市場：流通チャネル別、推定・動向分析

ギランバレー症候群市場：流通チャネルセグメントダッシュボード
ギランバレー症候群市場：流通チャネル変動分析、2024年と2030年
病院薬局
小売薬局
その他の薬局

第8章ギランバレー症候群市場：地域別、推定・動向分析

ギランバレー症候群の市場シェア、地域別、2024年と2030年、100万米ドル
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- デンマーク
- ノルウェー
- スウェーデン
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート
- 南アフリカ

第9章競合情勢

主要市場参入企業による最近の動向と影響分析
企業分類
企業市場シェア分析、2024年
企業ヒートマップ分析、2024年
企業プロファイル
- AbbVie Inc.
- Biogen
- Cadila Pharmaceuticals
- CSL
- F. Hoffmann-La Roche Ltd.
- GSK plc.
- Grifols SA
- LGM Pharma.
- Merck &Co., Inc.
- Octapharma AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited

図表

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 4 Global Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 5 Global Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 8 North America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 9 North America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 North America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 U.S. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 12 U.S. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 13 U.S. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 14 U.S. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 15 Canada Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 16 Canada Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 17 Canada Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 18 Canada Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Mexico Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 20 Mexico Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 21 Mexico Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 Mexico Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Europe Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 24 Europe Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 25 Europe Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 26 Europe Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Germany Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 28 Germany Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 29 Germany Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 30 Germany Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 31 U.K. Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 32 U.K. Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 33 U.K. Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 U.K. Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 France Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 36 France Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 37 France Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38 France Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 39 Italy Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 40 Italy Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 41 Italy Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 42 Italy Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Spain Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 44 Spain Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 45 Spain Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 46 Spain Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Denmark Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 48 Denmark Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 49 Denmark Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 50 Denmark Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Sweden Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 52 Sweden Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 53 Sweden Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 54 Sweden Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Norway Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 56 Norway Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 57 Norway Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 58 Norway Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 China Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 64 China Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 65 China Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 66 China Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Japan Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 68 Japan Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 69 Japan Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 70 Japan Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 71 India Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 72 India Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 73 India Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 74 India Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 75 South Korea Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 76 South Korea Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 77 South Korea Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 78 South Korea Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 79 Australia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 80 Australia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 81 Australia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 82 Australia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Thailand Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 84 Thailand Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 85 Thailand Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 86 Thailand Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 87 Latin America Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 88 Latin America Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 89 Latin America Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 90 Latin America Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 91 Brazil Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 92 Brazil Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 93 Brazil Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 94 Brazil Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 95 Argentina Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 96 Argentina Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 97 Argentina Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 98 Argentina Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 100 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 101 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 102 Middle East & Africa (MEA) Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 103 South Africa Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 104 South Africa Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 105 South Africa Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 106 South Africa Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 111 UAE Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 112 UAE Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 113 UAE Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 114 UAE Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 115 Kuwait Guillain-Barre Syndrome (GBS) Market, by Type, 2018 - 2030 (USD Million)
Table 116 Kuwait Guillain-Barre Syndrome (GBS) Market, by Therapeutics, 2018 - 2030 (USD Million)
Table 117 Kuwait Guillain-Barre Syndrome (GBS) Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 118 Kuwait Guillain-Barre Syndrome (GBS) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Guillain-Barre syndrome market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook, 2024 (USD billion)
Fig. 11 Market trends & outlook
Fig. 12 Porter's five force analysis
Fig. 13 PESTEL analysis
Fig. 14 Guillain-Barre Syndrome market: Therapeutics outlook and key takeaways
Fig. 15 Guillain-Barre Syndrome market: Therapeutics movement analysis
Fig. 16 Intravenous Immunoglobulin (IVIG) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Plasma Exchange market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Guillain-Barre Syndrome market: Type outlook and key takeaways
Fig. 20 Guillain-Barre Syndrome market: Type movement analysis
Fig. 21 Acute Inflammatory Demyelinating Polyneuropathy (AIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Miller Fisher Syndrome (MFS) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Acute Motor Axonal Neuropathy (AMAN) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Guillain-Barre Syndrome market: Route of administration outlook and key takeaways
Fig. 27 Guillain-Barre Syndrome market: Route of administration movement analysis
Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Parenteral market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Guillain-Barre Syndrome market: Distribution channel outlook and key takeaways
Fig. 31 Guillain-Barre Syndrome market: Distribution channel movement analysis
Fig. 32 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Other pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Regional Marketplace: Key Takeaways
Fig. 36 Regional Outlook, 2024 & 2030
Fig. 37 Global Guillain-Barre syndrome market, Region Movement Analysis
Fig. 38 North America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 39 U.S. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 40 Canada Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 41 Mexico Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 42 Europe Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 43 Germany Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 44 U.K. Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 45 France Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 46 Italy Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 47 Spain Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 48 Denmark Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 49 Sweden Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 50 Norway Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 52 Japan Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 53 China Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 54 India Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 55 Australia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 56 South Korea Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 57 Thailand Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 58 Latin America Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 59 Brazil Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 60 Argentina Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 61 Middle East and Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 62 South Africa Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 64 UAE Guillain-Barre syndrome market, 2018 - 2030 (USD Million)
Fig. 65 Kuwait Guillain-Barre syndrome market, 2018 - 2030 (USD Million)

Product Code: GVR-4-68040-200-8

Guillain-Barre Syndrome Market Growth & Trends:

The global guillain-Barre syndrome market size is anticipated to reach USD 1.03 billion by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barre Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights:

Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barre Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG's proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.
Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.
Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.
Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.
North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
  - 3.3.1.1. Increasing prevalence of Guillain-Barre Syndrome (GBS)
  - 3.3.1.2. Government regulations and guidelines
  - 3.3.1.3. Advancements in treatment options
- 3.3.2. Market Restraints Analysis
  - 3.3.2.1. Side effects and adverse reactions
  - 3.3.2.2. High cost treatment
3.4. Guillain-Barre Syndrome Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

4.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
4.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
4.3. Intravenous Immunoglobulin (IVIG)
- 4.3.1. Intravenous Immunoglobulin (IVIG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Plasma Exchange
- 4.4.1. Plasma Exchange Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Others
- 4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

5.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
5.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
5.3. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
- 5.3.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- 5.4.1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Miller Fisher Syndrome (MFS)
- 5.5.1. Miller Fisher Syndrome (MFS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Acute Motor Axonal Neuropathy (AMAN)
- 5.6.1. Acute Motor Axonal Neuropathy (AMAN) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other
- 5.7.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

6.1. Guillain-Barre Syndrome Market: Route of Administration Segment Dashboard
6.2. Guillain-Barre Syndrome Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
6.3. Parenteral
- 6.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Oral
- 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

7.1. Guillain-Barre Syndrome Market: Distribution Channel Segment Dashboard
7.2. Guillain-Barre Syndrome Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
7.3. Hospital Pharmacies
- 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail Pharmacies
- 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Other Pharmacies
- 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

8.1. Guillain-Barre Syndrome Market Share, By Region, 2024 & 2030, USD Million
8.2. North America
- 8.2.1. North America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
  - 8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
  - 8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. UK
  - 8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
  - 8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
  - 8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
  - 8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
  - 8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
  - 8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Norway
  - 8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Sweden
  - 8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. China
  - 8.4.2.1. China Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Japan
  - 8.4.3.1. Japan Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
  - 8.4.4.1. India Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. South Korea
  - 8.4.5.1. South Korea Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. Australia
  - 8.4.6.1. Australia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Thailand Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. Latin America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Brazil Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
  - 8.5.3.1. Argentina Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 8.6.2. Saudi Arabia
  - 8.6.2.1. Saudi Arabia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. UAE
  - 8.6.3.1. UAE Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. Kuwait
  - 8.6.4.1. Kuwait Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. South Africa
  - 8.6.5.1. South Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis, 2024
9.5. Company Profiles
- 9.5.1. AbbVie Inc.
  - 9.5.1.1. Participant's Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Recent Developments/ Strategic Initiatives
- 9.5.2. Biogen
  - 9.5.2.1. Participant's Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Recent Developments/ Strategic Initiatives
- 9.5.3. Cadila Pharmaceuticals
  - 9.5.3.1. Participant's Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Recent Developments/ Strategic Initiatives
- 9.5.4. CSL
  - 9.5.4.1. Participant's Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Recent Developments/ Strategic Initiatives
- 9.5.5. F. Hoffmann-La Roche Ltd.
  - 9.5.5.1. Participant's Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Recent Developments/ Strategic Initiatives
- 9.5.6. GSK plc.
  - 9.5.6.1. Participant's Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Recent Developments/ Strategic Initiatives
- 9.5.7. Grifols S.A.
  - 9.5.7.1. Participant's Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Recent Developments/ Strategic Initiatives
- 9.5.8. LGM Pharma.
  - 9.5.8.1. Participant's Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Recent Developments/ Strategic Initiatives
- 9.5.9. Merck & Co., Inc.
  - 9.5.9.1. Participant's Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product Benchmarking
  - 9.5.9.4. Recent Developments/ Strategic Initiatives
- 9.5.10. Octapharma AG
  - 9.5.10.1. Participant's Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product Benchmarking
  - 9.5.10.4. Recent Developments/ Strategic Initiatives
- 9.5.11. Pfizer Inc.
  - 9.5.11.1. Participant's Overview
  - 9.5.11.2. Financial Performance
  - 9.5.11.3. Product Benchmarking
  - 9.5.11.4. Recent Developments/ Strategic Initiatives
- 9.5.12. Takeda Pharmaceutical Company Limited
  - 9.5.12.1. Participant's Overview
  - 9.5.12.2. Financial Performance
  - 9.5.12.3. Product Benchmarking
  - 9.5.12.4. Recent Developments/ Strategic Initiatives

ギランバレー症候群の市場規模、シェア、動向分析レポート：治療法別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

ギランバレー症候群市場の成長と動向

ギランバレー症候群市場レポートハイライト

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章ギランバレー症候群市場の変数、動向、範囲

第4章ギランバレー症候群市場：治療法別、推定・動向分析

第5章ギランバレー症候群市場：タイプ別、推定・動向分析

第6章ギランバレー症候群市場：投与経路別、推定・動向分析

第7章ギランバレー症候群市場：流通チャネル別、推定・動向分析

第8章ギランバレー症候群市場：地域別、推定・動向分析

第9章競合情勢

List of Tables

List of Figures

Guillain-Barre Syndrome Market Growth & Trends:

Guillain-Barre Syndrome Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

ギランバレー症候群の市場規模、シェア、動向分析レポート：治療法別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

ギランバレー症候群市場の成長と動向

ギランバレー症候群市場レポートハイライト

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ギランバレー症候群市場の変数、動向、範囲

第4章 ギランバレー症候群市場：治療法別、推定・動向分析

第5章 ギランバレー症候群市場：タイプ別、推定・動向分析

第6章 ギランバレー症候群市場：投与経路別、推定・動向分析

第7章 ギランバレー症候群市場：流通チャネル別、推定・動向分析

第8章 ギランバレー症候群市場：地域別、推定・動向分析

第9章 競合情勢

List of Tables

List of Figures

Guillain-Barre Syndrome Market Growth & Trends:

Guillain-Barre Syndrome Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章ギランバレー症候群市場の変数、動向、範囲

第4章ギランバレー症候群市場：治療法別、推定・動向分析

第5章ギランバレー症候群市場：タイプ別、推定・動向分析

第6章ギランバレー症候群市場：投与経路別、推定・動向分析

第7章ギランバレー症候群市場：流通チャネル別、推定・動向分析

第8章ギランバレー症候群市場：地域別、推定・動向分析

第9章競合情勢